Vitalia Sergeevna Novikova

Vitalia Sergeevna Novikova

Auto-generated profile, based on publicly available information

Vitalia Sergeevna Novikova

Koltzov Institute of Developmental Biology of the Russian Academy of Sciences, Moscow 119334, Russia

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
VKVictoria Alexandrovna Khotina
Victoria Alexandrovna Khotina
ALArthur Anatolievich Lee
Arthur Anatolievich Lee
DKDmitry Kashirskikh
Dmitry Kashirskikh
Olesya KlychkovaOlesya Klychkova
Olesya Klychkova
VNVitalia Sergeevna Novikova
Vitalia Sergeevna Novikova
TGTeymur Gasanov
Teymur Gasanov
Diabetic foot ulcers (DFU) are among the most severe complications of diabetes, resulting from a combination of metabolic dysregulation, vascular insufficiency, neuropathy, chronic inflammation, and impaired tissue repair, whereas diabetic foot infection (DFI) may develop within this compromised wound environment and frequently involves polymicrobial communities and biofilms. This review evaluates the mechanistic and translational basis for the use of antimicrobial peptides (AMP) in DFU and DFI, with emphasis on the diabetic wound microenvironment, polymicrobial ecology, endogenous AMP dysregulation, mechanisms of action, therapeutic development, and barriers to clinical translation. Hyperglycemia, ischemia, oxidative and proteolytic stress, and impaired innate immunity sustain inflammation, delay tissue repair, and promote microbial persistence. These conditions may also complicate antibiotic treatment through impaired tissue exposure and biofilm-associated tolerance. Depending on the peptide and experimental context, AMP may provide direct antimicrobial or antibiofilm activity and may also exert immunomodulatory or pro-reparative effects involving inflammatory signaling, angiogenesis, keratinocyte and fibroblast migration, and re-epithelialization. Approaches under investigation include engineered peptides, combination regimens, and local biomaterial-based platforms, including hydrogels, dressings, scaffolds, and nanoparticle-conjugated systems. Clinical translation remains constrained by proteolytic instability, potential host-tissue toxicity, limited selectivity, limited predictive value of preclinical models, heterogeneous clinical populations, nonstandardized endpoints, and manufacturing and regulatory requirements. Preclinical evidence supports further evaluation of approaches for local delivery of AMP, whereas clinical evidence in DFU and DFI remains limited and heterogeneous, with no AMP-based intervention yet demonstrating sufficiently consistent clinical benefit to support routine use.

Verified
Journal Article
Open access
PDF file
OVOlga Evgenevna Voronko
Olga Evgenevna Voronko
VNVitalia Sergeevna Novikova
Vitalia Sergeevna Novikova
Olesya KlychkovaOlesya Klychkova
Olesya Klychkova
MMMargarita Pavlovna Markina
Margarita Pavlovna Markina
ALArthur Anatolievich Lee
Arthur Anatolievich Lee
TGTeymur Gasanov
Teymur Gasanov
This review summarizes current knowledge on the role of human cathelicidin LL-37 in the regulation of apoptosis. LL-37 can modulate programmed cell death pathways, exerting either proapoptotic or antiapoptotic effects depending on various factors, such as cell type and peptide concentration. Data on LL-37 derivatives and their involvement in apoptosis are also discussed. Understanding the molecular mechanisms underlying LL-37 regulation of apoptosis is necessary to expand the therapeutic potential of this peptide in various pathological conditions, including cancer.